Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 75

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 75
---
45,459 46,174 45,867 46,337 Computation of diluted securities:2025 Notes if-converted method adjustment— 4,122 — 4,865    Dilutive effect of RSUs— 239 — 162 Dilutive effect of ESPP share options— 4 — 2    Weighted average common shares outstanding—diluted45,459 50,539 45,867 51,366 Net income per common share:   Basic net (loss) income per common share$(0.11)$0.41 $(0.00)$0.60    Diluted net (loss) income per common share$(0.11)$0.39 $(0.00)$0.58 The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net (loss) income per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Weighted average number of stock options6,858 7,311 6,921 7,486 2025 Notes2,821 — 2,821 — Weighted average number of RSUs4,703 1,304 4,417 1,267 Weighted average ESPP share options101 — 102 26       Total14,483 8,615 14,261 8,779 

NOTE 14—INCOME TAXES 

(Loss) income before income taxes and income tax expense are as follows (dollar amounts in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(Loss) income before income taxes:   Domestic$(4,214)$36,996 $6,459 $50,653    Foreign2,287 (412)320 (429)Total (loss) income before income taxes$(1,927)$36,584 $6,779 $50,224 Income tax expense$2,920 $17,698 $6,814 $22,359 Effective tax rate(152)%48 %101 %45 %

Pacira BioSciences, Inc.  |  Q2